AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Wave Life Sciences Ltd. Director's Dealing 2018

Jan 26, 2018

31900_dirs_2018-01-25_0a663c99-a426-4740-add5-2359fe2d5ded.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2018-01-23

Reporting Person: Panzara Michael A. (Franchise Lead, Neurology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-23	Ordinary Shares	A	17500	$0.00	Acquired	39736	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-23	Share Option (right to buy)	$40.05	A	35000	Acquired	2028-01-23	Ordinary Shares (35000)	Direct

Footnotes

F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022.

F2: The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022.